Merck (NYSE:MRK) Shatters Profit Guidance for Fiscal Year 2013; Fiscal Q4 Net Income Tumbles – MRK, GSK, NVS, BMY, GILD, JNJ, HLF, TEVA, CLSN

The Whitehouse Station, New Jersey-based Merck & Co, Inc’s (NYSE:MRK) current year profit forecasts tumbles as generic rivalry to its best selling medicine Singular will damage results.

The drug giant announced that earnings will be in the range of $3.60 to $3.70 per share without special items current year, align with the $3.69 median forecasts of 20 analysts’ gathered by Bloomberg.

Merck announced in a statement that adjusted earnings were $3.82 per share in 2012. Sales current year will be almost flat from 2012 while revenue was $47.3 billion in previous year.

The drug maker announced that fiscal fourth-quarter profit tumbled 7.3% to $1.4 billion or 46 cents per share. Earnings were 83 cents per share without special items, surpassing by 2 cents the median of 17 analyst forecasts gathered by Bloomberg.

Its competitors include GlaxoSmithKline plc (ADR) (NYSE:GSK) that rose +0.37% to $45.78 with the total traded volume of 1.48 million shares and Novartis AG (ADR) (NYSE:NVS) that dropped -0.77% to $68.34 with the total traded volume of 850,544.00 shares.

Other Healthcare stocks with bullish trend include Bristol Myers Squibb Co (NYSE:BMY) up 1.74% to $36.77, Gilead Sciences, Inc (NASDAQ:GILD) up 3.43% to $40.79 and Johnson & Johnson (NYSE:JNJ) up 0.47% to $74.30, whereas with bearish trend include Herbalife Ltd (NYSE:HLF) down -3.69% to $34.99, Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) down -0.61% to $37.76 and Celsion Corporation (NASDAQ:CLSN) down -13.91% to $1.30.

Merck & Co., Inc (NYSE:MRK) stock’s trade at beginning with a price of $42.24 and the current trading session climbed at a high of $42.75 other than the stock finally basic -3.03% to $41.94.

Shares price of MRK moved down from its 20 days moving average with -2.12% and remote negatively from 50 days moving average with -2.59%. MRK current year earnings per share experienced an addition with +634.53% while its current quarter performance remained -5.38%.

MRK has a trade volume of 20.22 million shares is higher as compared to average trading capacity of 14.30 million shares.

MRK last month stock price volatility remained 0.82%. In its share capital MRK has 2.73 billion outstanding shares among them 2.73 billion shares have been floated in market exchange. MRK stock institutional ownership remained 64.57% while insider ownership included 0.03%.

The stock is ahead its 52 week low with 16.18% and lagging behind from its 52 week high price with -2.68%. Company’s beta coefficient included 0.54. Beta factors measures the amount of market risk associated with market trade.

DO NOT TRADE ANY STOCK WITHOUT LEVEL 2 STOCK QUOTES! delivers it's user with the most in-depth Level 2 Quotation System available on the Planet! NO Downloads, NO Widgets, NO Plugins required! Stay on TOP of your trades with! CLICK HERE TO START YOUR FREE 30-DAY TRIAL

This entry was posted in Healthcare, Latest Headlines and tagged , , , , , , , , , , , , , , , , , , , , , , , , , , . Bookmark the permalink.